30 results about "Abdominal aneurysm" patented technology

The invention discloses a screening method of a protein marker combination, which is used for risk prediction of abdominal aortic aneurysm or ruptured abdominal aortic aneurysm, and optimizes the stability of a protein expression profile by constructing an initial protein expression profile; screening differential expression proteins by adopting statistical analysis, and preliminarily locking candidate proteins remarkably associated with a disease endpoint based on survival analysis or a risk regression model; performing cross validation by combining a sparse constraint algorithm and a nonlinear feature selection algorithm, and extracting a robust core marker; the independent contribution degree of each marker is evaluated through the standardized weight, and finally the optimal protein combination for disease prediction or diagnosis is determined. According to the method, six core proteins obtained through multi-algorithm cross screening can be detected in serum, multivariable logistic regression and external verification set performance both show good robustness, and an aorta protein fingerprint feature set which can be popularized and explained is formed.

The application provides a multifunctional nano particle for targeting abdominal aortic aneurysm and a preparation method and application thereof, and belongs to the field of nanobiomedicine, wherein polyphenol oxidation self-polymer nanoparticles are used as carriers, doxycycline is loaded, and a targeting ligand cRGD is modified on the surface of the nano carrier; the neovasculature in the media and adventitia of AAA sites helps accumulation of the nanoparticles in the abdominal aortic aneurysm, and the integrin αν3 beta receptor highly expressed on the surface of the diseased cell membrane can recognize the cRGD with high affinity, and then mediate the targeted endocytosis of the nanoparticles; after intravenous injection, the nanoparticles can be effectively enriched in the lesion site and achieve long-term retention, and can release DC in response to the high ROS level in the tumor microenvironment; the drug is rapidly released to take effect, and the non-specific toxic side effects are reduced; the free radical scavenging capacity of the nanoparticles can be synergized with the DC activity to treat AAA through multiple mechanisms such as anti-inflammatory, antioxidant, macrophage repolarization promotion, anti-apoptosis and calcification inhibition, and MMPs inhibition.

The application belongs to the technical field of biological medicine, and relates to application of a CXCL14 inhibitor in preparation of a drug for preventing or treating abdominal aortic aneurysm of a patient. The inhibitor effectively eliminates the gender difference of abdominal aortic aneurysm by specifically blocking the combination of CXCL14 and its receptor CXCR4, significantly reduces aortic macrophage infiltration and PDGFRA + macrophage accumulation in the progress of abdominal aortic aneurysm, reduces the degree of collagen degradation and elastic fiber damage, and thus inhibits the pathological progress of abdominal aortic aneurysm. The application provides a new target and drug combination for precise treatment of male abdominal aortic aneurysm, and has clear clinical application value.

The invention relates to the technical field of biological medicines, and particularly relates to a method for researching the influence of silencing or inhibiting a UBE2G1 gene on the growth of abdominal aortic aneurysm by constructing a UBE2G1 gene function deletion mouse model. Results show that silence or inhibition of UBE2G1 gene expression can inhibit growth of abdominal aortic aneurysm, alleviate destruction of elastic fibers of arterial tissues, reduce levels of inflammatory factors such as TNF-alpha, IL-1beta and IL-6 in a body and inhibit polarization of macrophage M1. According to the invention, a certain theoretical basis is provided in the aspect of treatment of abdominal aortic aneurysm by means of biotechnology, and the UBE2G1 gene (or protein) can be used as a drug target for treatment of abdominal aortic aneurysm.

The invention provides an abdominal aortic aneurysm early prediction model construction method, system and device and a medium. According to the method, a balanced research queue is constructed through fusion of multi-modal data (ultrasonic images, biochemical indexes and lipidomics) and tendency score matching, so that the accuracy of early risk identification of the abdominal aortic aneurysm and the model robustness are remarkably improved; furthermore, on the basis of a risk migration strategy, the discrimination capability of the complex deep learning model is migrated to a simplified logistic regression model which only needs a simplest lipid feature set and basic demographic information, so that high prediction performance is maintained, model lightweight, parameter immobilization and clinical interpretability are realized, the detection cost and the operation complexity are greatly reduced, and the detection efficiency is improved. A high-precision risk prediction technology can be conveniently deployed in a basic medical scene, and finally an abdominal aortic aneurysm early screening solution with high precision, high interpretability and wide applicability is formed.

The invention relates to an abdominal aortic aneurysm filling system and treatment system, the filling system comprises a filling assembly, the filling assembly comprises at least two filling blocks, each filling block adopts shape memory polymer foam, and each filling block has a compressed loading state and an implantation state of expanding at a preset position; the interventional catheter is used for containing the filling assembly to implement interventional delivery, and the filling blocks are sequentially arranged in the extending direction of the interventional catheter in the loading state; the connecting shaft is arranged in the interventional catheter in a sliding mode, the far-end portion of the connecting shaft sequentially penetrates through and is connected with the filling blocks so as to carry the filling blocks to be released from the far-end side of the interventional catheter into the abdominal aortic aneurysm, and the far-end portion of the connecting shaft is configured to be spirally wound around a space axis in a pre-shaping mode. The surgical operation process is simplified, the filling blocks are arranged relatively orderly after being released and expanded, the space filling rate is high, and the surgical treatment effect is further improved.

The invention belongs to the technical field of medicines, and particularly relates to a prodrug for supplementing NAD < + >, which is an NAMPT agonist YB8, and an application of the prodrug in prevention and treatment of abdominal aortic aneurysm. The invention discloses a prodrug YB8 capable of specifically activating nicotinamide phosphoribosyltransferase (NAMPT), and the prodrug YB8 can effectively improve the level of NAD + (nicotinamide adenine dinucleotide) in cells, so that the degenerative change of a vascular structure is slowed down, the purposes of protecting blood vessels and treating abdominal aortic aneurysm are achieved, and the YB8 is proved to be used as a specific activator of NAMPT for the first time. The multi-target treatment effect is achieved by improving the blood vessel NAD + level; the discovery provides a brand new strategy for the drug treatment of abdominal aortic aneurysm, and the treatment advantages are as follows: ultrasonic imaging proves that the tumor progress can be obviously inhibited; the discovery lays an important foundation for developing clinical treatment of abdominal aortic aneurysm based on NAD + metabolism regulation.

The invention discloses application of a biomarker in preparation of a product for diagnosing abdominal aortic aneurysm, a kit and a use method, the biomarker has the advantages of high sensitivity, strong specificity and high accuracy, and the detection method is simple and rapid and has important significance in early screening of abdominal aortic aneurysm. The biomarker is any one of the following exosome proteins or a combination thereof: fibrinogen beta chain, fibronectin, lysosome related membrane glycoprotein 2 and histone H4.

The invention relates to application of a JAML gene in preparation of an abdominal aortic aneurysm resisting medicine, and belongs to the technical field of biological medicine. The nucleotide sequence of the JAML gene is as shown in SEQ ID No.1. The application of the JAML gene in preparation of the abdominal aortic aneurysm resisting medicine comprises the following two aspects: (1) applying the JAML gene as an action target to preparation of the abdominal aortic aneurysm resisting medicine; and (2) applying the JAML gene as an action target to screening of drugs for resisting abdominal aortic aneurysm. According to the invention, a gene knockout mouse of which the smooth muscle specifically knockout JAML is constructed, and then the mouse abdominal aortic aneurysm model is constructed by subcutaneously pumping AngII, so that the morbidity of abdominal aortic aneurysm can be obviously reduced after the JAML gene is knocked out; therefore, a theoretical basis is provided for preparing or screening drugs or preparations for inhibiting smooth muscle cell JAML gene expression as alternative drugs or preparations for resisting abdominal aortic aneurysm.

The invention relates to the technical field of medical instruments, in particular to an abdominal aortic aneurysm cavity support auxiliary positioning device. An inner tube and a positioning assembly are coaxially arranged in the outer sheath tube in a sleeving manner; the outer sheath tube is connected with the near end of the inner tube, so that the relative positions of the outer sheath tube and the inner tube can be kept consistent; the positioning assembly is arranged on the periphery of the inner tube in a sleeving mode and can slide between the outer sheath tube and the inner tube. A penetrating through hole is formed in the center of the inner tube, and a guide wire can penetrate through the penetrating through hole and slide in the inner tube. The auxiliary positioning device for the abdominal aortic aneurysm cavity support is simple in structure, easy and convenient to operate and capable of effectively assisting in positioning a main body support short iliac branch opening in an abdominal aortic aneurysm cavity, the butt joint efficiency of the main body support short iliac branch and an iliac branch extension support is improved, the operation time is shortened, the operation risk is reduced, and ray damage is reduced.

The invention relates to application of an Arteridin gene as a biomarker in preparation of a product for auxiliary diagnosis of abdominal aortic aneurysm, clinical specimens and animal experiments find that the expression of Arteridin in occurrence of abdominal aortic aneurysm is remarkably increased, which indicates that Arteridin can be used as the biomarker for auxiliary diagnosis of abdominal aortic aneurysm; the invention also relates to a product for down-regulating the expression of Arterin and an application of the product in preparation of drugs for treating abdominal aortic aneurysm, the product comprises siRNA and shRNA of a targeted Arterin gene and AAV for coding the sequence of the shRNA, and after specific knockdown of Arterin by smooth muscle cells is realized, in an Elatase-induced abdominal aortic mouse model, the expression of Arterin is reduced, and the expression of Arterin is reduced. The diameter of the aneurysm is reduced, the occurrence rate is reduced, the elastin destruction degree is reduced, the expression quantity of vascular remodeling genes MMP2 and MMP9 is reduced, and the difference is obvious compared with that of a control group; the result shows that Arteridin is expected to become a target spot for treating abdominal aortic aneurysm.

The invention discloses an application of Anti-TSLP (Transcriptional Stem Like Protein) in prevention or treatment of abdominal aortic aneurysm. The Anti-TSLP is an anti-TSLP (Transcriptional Stem Like Protein) monoclonal antibody. The application of Anti-TSLP as a monoclonal antibody drug in prevention or treatment of abdominal aortic aneurysm is found for the first time. By intraperitoneal injection of Anti-TSLP and neutralization of TSLP pro-inflammatory cytokines, macrophage M1 / M2 phenotype can be effectively regulated, macrophage-mediated inflammatory response can be regulated and controlled, abdominal aortic aneurysm can be relieved, and a potential treatment scheme is provided for precise treatment of patients with clinical abdominal aortic aneurysm.

The invention relates to the technical field of medical instruments, and discloses a form-adaptive aortic dissection false cavity or aneurysm cavity thrombosis promoting embolism device which comprises a double-layer metal grid spindle-shaped skeleton of a hollow structure. Comprising a connecting point at the upper end and the lower end and an arc-shaped side face connected between the two points. The isolating membrane is located between the double-layer metal grid fusiform skeletons, and the double-layer metal grid fusiform skeletons are small in size after being compressed, can be quickly released and automatically adapt to the shape of an aortic dissection false cavity or an aneurysm cavity, so that the aneurysm cavity or the false cavity is fully blocked, and thrombosis of the aneurysm cavity or the false cavity is promoted. The device is simple in structure, convenient to operate, capable of adapting to the shape of an interlayer false cavity to be fully filled, good in blood flow isolation effect, capable of rapidly promoting thrombosis and remodeling of the false cavity, free of reverse compression of a true cavity and capable of being applied to occasions where embolism needs to be conducted on abdominal aortic aneurysm cavities and other branch arteries.

The application discloses application of CCR6 gene in preparation of an anti-abdominal aortic aneurysm medicine and belongs to the technical field of medicines. The application selects CCR6-siRNA interference technology, constructs an adeno-associated virus expression vector, inhibits expression of a mouse CCR6 gene, and constructs a mouse abdominal aortic aneurysm model by subcutaneous pumping of angiotensin II, finds that inhibition of the CCR6 gene can significantly reduce the incidence of abdominal aortic aneurysm and inhibit the occurrence and development of abdominal aortic aneurysm, and provides a theoretical and experimental basis for preparation and screening of a medicine or preparation for inhibiting expression of the CCR6 gene as a candidate medicine or preparation for resisting abdominal aortic aneurysm. The application prepares an adeno-associated virus for inhibiting the CCR6 gene, and finds that inhibition of the CCR6 gene can significantly inhibit the occurrence and development of abdominal aortic aneurysm by injecting the adeno-associated virus for inhibiting the CCR6 gene into a mouse tail vein.

This invention discloses the application of ML-SA5, a highly specific small molecule agonist of TRPML1, for the preparation of drugs against aortic aneurysms or aortic dissections. An aortic aneurysm model was constructed, and an aortic dissection model was established using Fbn1 point mutations. The severity of aortic aneurysms or aortic dissections in control and experimental mice was assessed using small animal ultrasound and aortic morphology staining. Results showed that intraperitoneal injection of ML-SA5 or overexpression of TRPML1 significantly reduced abdominal aortic aneurysm / dissection lesions in mice; it also reduced elastic fiber degradation and smooth muscle cell destruction in abdominal aortic aneurysms, decreased the increase in media thickness and collagen fiber deposition in aortic dissections, further improving the progression and histopathological damage of abdominal aortic aneurysms / dissections. This drug showed good therapeutic effects in animal experiments, with high safety and few toxic side effects, and can be used as a drug to inhibit the progression of aortic aneurysms / dissections.

The invention provides application of an adeno-associated virus overexpressing CTH in preparation of drugs for extravascular treatment of abdominal aortic aneurysm. When the adeno-associated virus overexpressing CTH is applied to the periphery of abdominal aortic aneurysm, fracture of elastic fibers of abdominal aorta can be reduced, collagen deposition can be reduced, infiltration of macrophages (CD68) can be reduced, secretion of matrix metalloproteinase can be reduced, degradation of extracellular matrixes can be reduced, and occurrence and development of AAA can be relieved.

The application belongs to the technical field of biological medicine and nanomaterials, and particularly relates to a nano system for targeted photothermal-chemotherapy synergistic treatment of abdominal aortic aneurysm as well as a preparation method and application thereof. The system is a mesoporous polydopamine-coated gold nanorod cluster (AuM) nanoparticle co-loaded with one or more traditional Chinese medicine ingredients and modified by c(RGDfK) cyclic peptide. The preparation comprises the following steps: taking chloroauric acid and dopamine hydrochloride as raw materials, synthesizing AuM in the presence of a reaming agent and a template agent by a one-step method; further loading a large amount of drugs in the mesopores to obtain drug-loaded nanoparticles; and finally grafting a targeting peptide on the surface of the nanoparticles to obtain the final product. The system has the characteristics of targeting macrophages and smooth muscle cells, NIR-Ⅱ photothermal conversion and photothermal response drug release. The in-vitro and in-vivo experimental results show that the system can realize local photothermal treatment and precise drug release under NIR-Ⅱ light, and inhibit aortic dilation through various cell behaviors, thereby providing a nano preparation with clinical transformation potential for precise treatment of abdominal aortic aneurysm.

The invention belongs to the field of biological medicines, particularly discloses an application of NiMn-PB in preparation of an abdominal aortic aneurysm protection medicine, and discloses that NiMn-PB can obviously improve degradation of an aortic elastic fibrous layer caused by Ang II treatment and can relieve immune cell infiltration, inflammation release, ferroptosis and angiogenesis in aorta; after Ang II treatment, NiMn-PB is used for intervention, occurrence and development of the abdominal aortic aneurysm induced by Ang II can be relieved, and it is indicated that NiMn-PB can be used for preparing the medicine for relieving the abdominal aortic aneurysm.

This invention belongs to the field of biomedical technology, specifically relating to the application of metabolic markers in the preparation of products for diagnosing abdominal aortic aneurysms. The metabolic markers include 5-δ-hydroxybutylhydantoin, 1-α-amino acid, and PGF. 2α The present invention provides one or more of the following metabolites: D-pyroglutamic acid, nicotinic glucuronide, cysteine ​​glutathione disulfide, or Trp-P-1. Experiments have confirmed that the seven metabolites, alone or in combination, have good specificity and sensitivity as metabolic markers for diagnosing abdominal aortic aneurysms.

There is provided a method and a system for training and using one or more machine learning (ML) models to predict abdominal aortic aneurysm (AAA) growth based on at least one image of a given patient having been previously diagnosed with AAA. Baseline and follow-up images of patients having AAA are received and compared to determine difference in aortic areas, and each baseline image is labelled as showing significant AAA growth or non-significant AAA growth based on the determined differences. Features are extracted from the aortic areas of the baseline images and include one or more of shape features, texture features or deep features. ML models are trained to classify baseline images as showing significant AAA growth or not based on the extracted features. Calcification accumulation in the baseline images is also determined as an indicator of AAA growth.

The invention provides application of an adeno-associated virus overexpressing CBX3 in preparation of a medicine for extravascular treatment of abdominal aortic aneurysm. When the adeno-associated virus overexpressing CBX3 is applied to the periphery of abdominal aortic aneurysm, fracture of elastic fibers of abdominal aorta can be reduced, collagen deposition can be reduced, infiltration of macrophages (CD68) can be reduced, secretion of matrix metalloproteinase can be reduced, degradation of extracellular matrixes can be reduced, and occurrence and development of AAA can be relieved.

This invention discloses a magnetic resonance imaging (MRI) contrast agent for targeted detection of collagen molecular structural denaturation, its preparation method, and its application. The general chemical formula of this MRI contrast agent is: [X] m -L-(GfO) n Among them, (GfO) n [n] is a collagen hybrid peptide, where n is a positive integer between 6 and 12; L is a linker, comprising amino acids and / or amino acid derivatives; [X] is a paramagnetic metal complex, composed of a chelating agent and paramagnetic metal ions; m represents the number of paramagnetic metal complexes, where m is a positive integer between 1 and 12. The magnetic resonance contrast agent of this invention can target and detect degenerated collagen, exhibiting higher lesion specificity and detection sensitivity compared to conventional targeted contrast agents that rely on differences in collagen content for imaging. Furthermore, this magnetic resonance contrast agent can significantly enhance the magnetic resonance signal of damaged and degenerated cartilage, Achilles tendon, and abdominal aortic aneurysm, facilitating the early diagnosis of collagen degeneration-related diseases.

This invention discloses the use of substances that interfere with the expression of coagulation factor X (F10) or inhibit the activity of its activated form, activated coagulation factor X (FXa), in the preparation of drugs for the prevention or treatment of abdominal aortic aneurysm (AAA), belonging to the field of biomedicine. This invention is the first to discover that endothelial-derived F10 / FXa is significantly upregulated in the early stages of AAA development. FXa can disrupt the stability of the endothelial tight junction protein ZO-1 through a non-coagulation-dependent pathway, driving vascular barrier dysfunction and AAA progression. In vivo experiments have confirmed that inhibiting F10 expression or FXa activity can significantly reduce the AAA tumorigenesis rate and inhibit aortic dilation, providing a novel target and intervention strategy for the early prevention and drug treatment of AAA.

Systems and methods for repairing aneurysms (e.g., abdominal aortic aneurysms) are provided. The systems and methods provide a stent graft system having a first stent and a main graft body, where the main graft body is configured to be inserted through a blood vessel into a target blood vessel. In some examples, the first stent and the main graft body may be in a substantially end-to-end configuration. In some examples, the stent graft systems and methods are configured for use in a single arterial puncture hole or incision, such as in a blood vessel having a diameter less than or equal to the femoral artery diameter of the same patient or subject.

The invention belongs to the technical field of biological medicines, and relates to application of a CXCL14 inhibitor in preparation of a medicine for preventing or treating abdominal aortic aneurysm of a patient. The inhibitor effectively eliminates the sex difference of the abdominal aortic aneurysm by specifically blocking the combination of CXCL14 and a receptor CXCR4 thereof, significantly reduces aortic macrophage infiltration and PDGFRA + macrophage accumulation in the progress process of the abdominal aortic aneurysm, and reduces the collagen degradation and elastic fiber destruction degrees, thereby inhibiting the pathological progress of the abdominal aortic aneurysm. The invention provides a new target spot and a medicine composition for precise treatment of male abdominal aortic aneurysm, and has a definite clinical application value.

The present invention relates to the technical field of drugs for gene therapy, in particular to the use of the Kif13b gene as a drug target in drugs. The use comprises the use in screening drugs for preventing, alleviating and / or treating fatty liver, atherosclerosis, abdominal aortic aneurysm and / or macrophage senescent inflammation.

The utility model discloses an abdominal aortic aneurysm susceptibility gene screening kit which comprises a tool box and an L-shaped working box, the L-shaped working box comprises a vertical part and a horizontal part, and the tool box is located on the horizontal part of the L-shaped working box; a plurality of clamping grooves are formed in the bottom in the horizontal part of the L-shaped working box, reagent strips are arranged in the clamping grooves, sample application areas, a strip I and a strip II are arranged on the reagent strips, sample adding holes are formed in the vertical part of the L-shaped working box and correspond to the reagent strips respectively, rotating covers are arranged on the sample adding holes, and bottom outlets of the sample adding holes correspond to the sample application areas of the reagent strips up and down. And a drawable baffle is arranged at the bottom of the sample adding hole. The kit is provided with a plurality of sample adding holes and a plurality of reagent strips, so that multi-gene joint detection is realized at the same time, and the detection result is more accurate.

The invention relates to an abdominal aortic aneurysm filling assembly based on a shape memory high polymer material and a treatment system, and the abdominal aortic aneurysm filling assembly comprises a filling part which comprises at least two unit sections which are connected in sequence, and a binding ring is hooped between every two adjacent unit sections; the interventional catheter is used for containing the filling piece, the far-end portion of the interventional catheter is configured to be capable of being spirally wound around a space axis, and in the loading state, all the unit sections are sequentially arranged in the extending direction of the interventional catheter; the delivery tube is arranged in the intervention catheter in a sliding and penetrating mode and used for providing abutting force towards the far end side for the filling piece in the releasing process. According to the abdominal aortic aneurysm filling assembly, all the unit sections can be arranged on the periphery of the trunk of the abdominal aortic covered stent in advance, the surgical operation process is simplified, all the unit sections are arranged relatively orderly after being released and expanded, the space filling rate is high, and the surgical treatment effect is further improved.

The application provides a kind of based on machine learning vascular disease type identification method, system, medium, terminal and program product, method includes: respectively obtaining atherosclerosis patient and abdominal aortic aneurysm patient in multiple time nodes collected ultrasonic imaging data, clinical physiological and biochemical data and lipidomics data;Based on feature extraction network model, ultrasonic imaging features, clinical physiological and biochemical features and lipidomics features are extracted, and multi-modal weighted fusion is carried out;Multi-modal fusion features with time sequence association information are input into machine learning model for training to obtain and deploy vascular disease type identification model, for identifying the vascular disease type of current user to be identified;Vascular disease type includes: atherosclerosis and abdominal aortic aneurysm.The application can realize the accurate and effective differentiation and risk assessment of atherosclerosis and abdominal aortic aneurysm under the same model framework, meet the actual needs of early screening of vascular diseases.

The application discloses a kind of abdominal aortic aneurysm serum protein fingerprint detection analysis method and system based on LASSO regression algorithm.The method is by optimizing serum sample pretreatment process, in combination with MALDI-TOFMS mass spectrometry technology and high-throughput proteomics data analysis, screening the differential expression protein in serum related to abdominal aortic aneurysm occurrence, development and rupture;Further utilize LASSO machine learning algorithm to construct risk assessment model based on key protein combination.The method of the application has the advantages of high sensitivity, good specificity, can effectively distinguish abdominal aortic aneurysm patients and normal population, and can accurately predict the rupture risk of abdominal aortic aneurysm, especially early small aneurysm, provide important tool and basis for clinical early diagnosis, risk stratification and personalized treatment decision.